Veeva Systems and BioMarin Pharmaceutical have announced a new partnership to strengthen their long-term relationship. This agreement will help BioMarin improve speed, flexibility, and efficiency in their operations, aiming to improve experiences for both healthcare professionals and patients.
The partnership will also target on using Veeva's software, data, services, and consulting. One of Veeva’s tools, Vault CRM, is gaining attention for helping companies improve their business. For example, Novo Nordisk has recently committed to using Veeva’s services. Other big companies like Roche, Bristol Myers Squibb, Gilead Sciences, and Merck are also set to use it in 2025.
In late 2025, BioMarin made headlines with a USD 4.8 billion acquisition of Amicus Therapeutics after already buying Inozyme Pharma for USD 270 million earlier in the year.
BioMarin’s global operations and manufacturing capabilities make these moves a strong fit, according to Hardy.
Executive Statement
According to Alexander Hardy, President and Chief Executive Officer of BioMarin, this strategic partnership marks an important next step in their digital evolution. They are excited by the opportunity to combine their scientific capabilities with Veeva’s technological leadership that they believe will enable them to bring their transformative medicines more quickly to patients around the world.
According to Veeva CEO Peter Gassner, their partnership with BioMarin has always been guided by a shared set of values, including product excellence, value realization, and customer success. Building on this foundation, he looks forward to how they can further support BioMarin as they advance important new medicines and reach even more patients around the world.
